CJC-1295 vs sermorelin
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
| Dimension | CJC-1295 | Sermorelin (GRF 1-29, formerly Geref) | Source |
|---|---|---|---|
| Molecule | Tetrasubstituted GRF(1-29) with the C-terminal DAC linker (30 residues) | Unmodified GRF(1-29) amide, the shortest fully active GHRH fragment | source |
| Half-life | 5.8 to 8.1 days | About 4.3 minutes (GRF 1-29, IV, normal men) | source |
| Exposure pattern | GH raised 2- to 10-fold for 6 or more days; IGF-I raised 1.5- to 3-fold for up to 11 days per dose | One brief GH pulse per injection (onset within 10 minutes, about 2 hours), axis rhythm untouched between doses | source |
| FDA approval history | Never approved for any use | Approved as Geref (1990 diagnostic, 1997 pediatric); discontinued 2008; FDA determined not withdrawn for safety or effectiveness | source |
| FDA compounding risk list | Listed by name, with identified serious adverse events (increased heart rate, systemic vasodilatory reaction) | Not listed (checked absence: zero mentions on the fetched page) | source |
| Human trial evidence | Randomized placebo-controlled healthy-adult trials of GH and IGF-I; no efficacy outcomes | Pediatric efficacy trials from the Geref era plus small adult hormone studies | source |
| Long-horizon data | Longest dosing 49 days; nothing beyond | 16-week class trial: IGF-I rose then returned toward baseline by trial end; durability never shown | source |
Sermorelin is the short-acting original; CJC-1295 is what happens when you weld that molecule to albumin. Same receptor, opposite time scales, and opposite regulatory biographies: sermorelin once held an FDA approval and left the market for commercial reasons, while CJC-1295 never held one and now carries FDA adverse-event citations. Our sister site sermorelinco.com covers sermorelin in monograph depth.
Sermorelin-side statements are cited to sources fetched for this pack (Soule 1994, Khorram 1997, the 2013 Federal Register determination, and the FDA risk-list absence check); nothing is borrowed from the sister site without an independent fetch. The approved-GHRH-analog slot in this class belongs to tesamorelin, covered in the related section.
Researching Sermorelin (GRF 1-29, formerly Geref) itself? Its dedicated guide site is at sermorelinco.com.